Derinat manufacturer

Posted on by admin

Derinat

There are contraindications. Before starting use, consult your doctor.

Currently, analogues (generics) of the drug are NOT FOR SALE in Moscow pharmacies.

All antiviral drugs and immunostimulants are here.

Table of contents:

Medicines to treat cold symptoms here.

You can post your question or review about the medicine (please, do not forget to indicate the name of the medicine in the text of the message) here.

Preparations containing sodium deoxyribonucleate (no ATC code):

Derinat - instructions for use:

Clinical and pharmacological group:

pharmachologic effect

An immunomodulator that affects cellular and humoral immunity. Derinat® stimulates reparative processes, has an anti-inflammatory effect, normalizes the condition of tissues during dystrophic changes of vascular origin.

The drug activates antiviral, antifungal and antimicrobial immunity, has a high reparative and regenerative effect.

When applied externally, Derinat® promotes the healing of trophic ulcers, infected wounds and deep burns, significantly accelerating epithelization. Under the influence of Derinat, scarless healing of ulcerative defects on the mucous membrane occurs.

Pharmacokinetics

Suction and distribution

Sodium deoxyribonucleate is quickly absorbed when applied topically and distributed through the lymphatic tract to organs and tissues.

Metabolism and excretion

Sodium deoxyribonucleate is metabolized in the body. It is excreted mainly by the kidneys and partly with feces.

Indications for use of the drug DERINAT® in the form of intramuscular injections:

  • radiation injuries;
  • hematopoiesis disorder;
  • myelosuppression and resistance to cytostatics in cancer patients, which developed against the background of cytostatic and/or radiation therapy (stabilization of hematopoiesis, reduction of cardio- and myelotoxicity of chemotherapy drugs);
  • stomatitis induced by cytostatic therapy;
  • peptic ulcer of the stomach and duodenum, erosive gastroduodenitis;
  • IHD;
  • obliterating diseases of the vessels of the lower extremities, stage II-III;
  • trophic ulcers, long-term non-healing wounds;
  • odontogenic sepsis, purulent-septic complications;
  • rheumatoid arthritis;
  • burn disease;
  • preoperative and postoperative periods (in surgical practice);
  • chlamydia, ureaplasmosis, mycoplasmosis;
  • endometritis, salpingoophoritis, endometriosis, fibroids;
  • prostatitis, benign prostatic hyperplasia;
  • chronic obstructive pulmonary diseases;
  • pulmonary tuberculosis, inflammatory diseases of the respiratory tract.

Indications for use of the drug DERINAT® in the form of a solution for external and local use:

As monotherapy:

  • prevention and treatment of ARVI;
  • acute respiratory infections;
  • inflammatory and dystrophic eye diseases;
  • inflammatory diseases of the oral mucosa.

As part of complex therapy:

  • chronic inflammatory diseases, fungal, bacterial and other infections of the mucous membranes in gynecology;
  • acute and chronic diseases of the upper respiratory tract (rhinitis, sinusitis /including frontal sinusitis, sinusitis/);
  • obliterating diseases of the lower extremities;
  • trophic ulcers;
  • gangrene;
  • infected and long-term non-healing wounds (including diabetes mellitus);
  • burns;
  • frostbite;
  • post-radiation necrosis of the skin and mucous membranes;
  • haemorrhoids.

Injection dosage regimen:

Derinat® is prescribed to adults intramuscularly (within 1-2 minutes) in an average single dose of 75 mg (5 ml of solution for intramuscular administration of 15 mg/ml) with an administration interval.

For ischemic heart disease, 5 ml of a 15 mg/ml solution is prescribed intramuscularly; the course of treatment is 10 injections.

For gastric and duodenal ulcers, 5 ml of a 15 mg/ml solution is prescribed intramuscularly every 48 hours, the course of treatment is 5 injections.

For oncological diseases - 5 ml (75 mg/m) intramuscularly, course of treatment - 10 injections.

In gynecology (endometritis, chlamydia, ureaplasmosis, mycoplasmosis, salpingoophoritis, fibroids, endometriosis) - 5 ml of a 15 mg/ml solution intramuscularly, a course of treatment - 10 injections.

In andrology (prostatitis, benign prostatic hyperplasia) - 5 ml of a 15 mg/ml solution intramuscularly, course of treatment - 10 injections.

For tuberculosis - 5 ml of a 15 mg/ml solution intramuscularly, course of treatment by injection.

For acute inflammatory diseases - 5 ml of a 15 mg/ml solution intramuscularly, a course of treatment by injection.

For chronic inflammatory diseases - 5 ml of a 15 mg/ml solution intramuscularly: the first 5 injections with an interval of 24 hours each, the subsequent ones - each with an interval of 72 hours, the total course of treatment is 10 injections.

When using a solution of 15 mg/ml, 2 ml intramuscular injections are carried out daily, recalculating, until the course dose is reached.

In children, the frequency of intramuscular administration of the drug is the same as in adults. For children under 2 years of age, the drug is prescribed in an average single dose of 7.5 mg (0.5 ml of solution for intramuscular administration of 15 mg/ml); for children aged 2 to 10 years, a single dose is determined at the rate of 0.5 ml of the drug per year of life; for children over 10 years of age, the average single dose is 75 mg (5 ml of solution for intramuscular administration of 15 mg/ml), the course dose is up to 5 injections of the drug.

Dosage regimen for the solution for external and local use:

Derinat® in the form of a solution for external and local use is prescribed depending on the location of the pathological process.

The drug is prescribed to children from the first day of life and to adults.

To prevent ARVI, instill 2 drops into each nasal passage 2-4 times a day for 1-2 weeks. When symptoms of a respiratory disease appear, the drug is instilled 2-3 drops into each nasal passage every 1-1.5 hours during the first day, then 2-3 drops into each nasal passage 3-4 times a day. The duration of the course of therapy is from 5 days to 1 month.

For inflammatory diseases of the nasal cavity and paranasal sinuses, the drug is instilled 3-5 drops into each nasal passage 4-6 times a day; duration of the course days.

For inflammatory diseases of the oral cavity, rinse the mouth with a solution of the drug 4-6 times a day (1 bottle for 2-3 rinses). Duration of therapy: days.

For chronic inflammatory diseases, fungal, bacterial and other infections in gynecological practice - intravaginal administration of tampons with the drug or irrigation of the vagina and cervix, 5 ml per procedure, 1-2 days.

For hemorrhoids, the drug is administered rectally using microenemas. The duration of treatment is 4-10 days.

In ophthalmological practice, for severe inflammatory and degenerative processes, Derinat® is instilled into the eyes, 1-2 drops 2-3 times a day.

For obliterating diseases of the lower extremities, in order to achieve a systemic effect, the drug is instilled 1-2 drops into each nasal passage 6 times, the course duration is up to 6 months.

In case of post-radiation necrosis of the skin and mucous membranes, with long-term non-healing wounds, burns, frostbite, trophic ulcers of various etiologies, gangrene, it is recommended to apply application bandages (gauze in 2 layers) with the application of the drug 3-4 to the affected areas or treat the affected surface with a drug from spray 4-5 times/course of treatment months.

Side effect

Possible: in patients with diabetes mellitus, a hypoglycemic effect is observed, which should be taken into account when monitoring blood glucose levels.

No side effects were identified with external or local use of the drug.

Contraindications to the use of the drug DERINAT®

  • hypersensitivity to the components of the drug.

Use of DERINAT® during pregnancy and breastfeeding

The patient should be warned that before using the drug during pregnancy and lactation, consultation with a doctor is necessary. If it is necessary to prescribe the drug during pregnancy, the expected benefit to the mother and the potential risk to the fetus should be assessed.

special instructions

Numerous experimental and clinical laboratory studies have proven the absence of mutagenic, teratogenic, embryotoxic, carcinogenic effects, allergenic properties, and cytogenetic effects; its moderate antimutagenic effect was revealed.

In case of gangrenous processes under the influence of the drug, spontaneous rejection of necrotic masses in the foci of rejection is observed with restoration of the skin. For open wounds and burns, an analgesic effect is noted.

Overdose

To date, no cases of overdose of Derinat® have been reported.

Drug interactions

When applied topically, it is incompatible with fat-based ointments and hydrogen peroxide.

Conditions for dispensing from pharmacies

The drug is approved for use as a means of OTC.

Storage conditions and periods

The drug should be stored out of the reach of children, in a dry place, protected from light at a temperature of 4° to 20°C. Shelf life – 5 years.

The contents of an opened bottle should be used within two weeks.

Source: http://xn—-7sbabkdpwufdsp9apq.xn--p1ai/derinat

Derinat manufacturer

bacteria and fungi penetrate into our nasopharynx.

Serious viral diseases can be avoided

healthy and undamaged, all germs

washed out with nasal secretions,

and do us no harm

Serious viral diseases can be avoided

the integrity of the mucosa and reduce its protective properties.

Various materials easily penetrate into the resulting damage.

microbes, infections, causing acute respiratory viral infections and influenza

and their complications

Serious viral diseases can be avoided

restores its integrity and protective

properties, and viruses again become

difficult to penetrate the body

Serious viral diseases can be avoided

Derinat - the basis

health for the whole family!

healing process and avoid complications

which leads to its death and the spread of new

viruses in the body

healing process and avoid complications

immunity responsible for

antibody formation and suppression

healing process and avoid complications

Derinata helps to recover faster

integrity of the mucous membrane, normalizing its barrier,

protective properties, thereby preventing

bacterial complications and early relapse

healing process and avoid complications

Thus

and without complications!

Hello, my child is 1.9 years old, we go to the nursery, he was very seriously ill, first with a sore throat, then pros.

Antonina, good afternoon!!

For what purpose did the doctor prescribe a solution for intramuscular injection?

Source: http://www.derinat.ru/

About company

In 1994, for the development, production and sale of new generation medicines based on the main component of a living cell - the DNA molecule - a specialized enterprise was formed - CJSC FP Tekhnomedservice, which later laid the foundation for the group of companies of the scientific and production campaigns Pharmpack and Immunnolex. Our Holding , one of the few in Russia that carries out scientific development, a full production cycle from substances to finished medicinal products and their distribution.Raw materials for the production of the substance are purchased in Russia, and all packaging materials are purchased from the factories of leading European manufacturers.

The promotion and distribution of drugs from the scientific and production holding is provided by the PharmPak company, founded in 2005. Effective promotion of the Holding's products requires close cooperation of the PharmPak company with federal and regional research institutes, the scientific medical community represented by the chief specialists of the Ministry of Health of the Russian Federation and the regional Health Departments of the constituent entities of the federation. Among them: Research Institute of Emergency Medicine named after. N.V. Sklifosovsky, Research Institute of Virology named after. DI. Ivanovsky RAMS, Russian Oncological Research Center named after. Academician N.N. Blokhin RAMS, Research Institute of Eye Microsurgery named after. S. Fedorov, Russian Military Medical Academy named after. CM. Kirov, St. Petersburg State Medical Academy named after. I.I. Mechnikov, Voronezh State Medical University named after. N.N. Burdenko, Mordovian State Medical University named after. N.P. Ogarev, Nizhny Novgorod, Tver, Samara, Chelyabinsk state medical academies, etc.

Our research and production holding annually increases the production volume of the drug: over the 10 years of the enterprise’s existence, the output of the finished product has increased 150 times! The emergence of a separate company “PharmPak” within the Holding, engaged in product promotion, made it possible to significantly increase the efficiency of product sales. Recently, distributors from other countries have shown increasing interest in the Holding’s products. Pharmaceutical companies from Slovakia, Yugoslavia, the Czech Republic, Bulgaria, and India have expressed interest in promoting Derinat to the market of their countries.

The products of our scientific and production Holding have been repeatedly awarded prestigious diplomas and prizes. In 1997, the Russian Biographical Institute declared the drug Derinat “Medicine of the Year.” In 2000, the company became a laureate of the “21st Century Enterprise” competition. The company is an official partner of the Kremlin Suppliers Guild and has received gratitude from the President of the Russian Federation for its great contribution to the development of the domestic economy. One of the latest awards is the international “Profession – Life” award for achievements in the field of medical production.

Our Holding is one of the few in Russia that carries out scientific development, a full production cycle from substances to finished drugs and their distribution.

The PharmPack company, founded in 2005, ensures the effective promotion of the Holding’s products.

Address: Moscow, Annensky proezd, building 7, building 1

Source: http://derinat.com/about/

Derinat for intramuscular administration instructions for use, contraindications, side effects, reviews

An immunomodulator that affects cellular and humoral immunity.

Active substance of the drug: non appropriated

ATX coding: L03A

Registration number: P No. 002916/01

Registration date: 09.22.03

Owner reg. credential: TEKHNOMEDSERVICE CJSC FP

Derinat release form for intramuscular administration, drug packaging and composition.

Solution for intramuscular administration 1.5% is transparent, colorless, without foreign inclusions.

Excipients: sodium chloride, water for injection.

5 ml - bottles (5) - blisters (1) - cardboard boxes.

The description of the drug is based on the officially approved instructions for use and approved by the manufacturer for the 2009 edition.

Pharmacological action Derinat for intramuscular administration

An immunomodulator that affects cellular and humoral immunity. The immunomodulatory effect of Derinat is due to its ability to stimulate the B-link of lymphocytes, activate T-helper cells and cells of the monocyte-macrophage system. Derinat activates the body's specific resistance, which leads to optimization of the inflammatory response and specific immune response to bacterial, viral and fungal antigens. The drug accelerates the metabolism and energy inside the cell, the synthesis of RNA and DNA. Activation of cellular immunity by Derinat increases the ability of natural killer cells to act on cells affected by viruses, Chlamydia spp., Staphylococcus aureus, Escherichia coli, Helicobacter pylori. Derinat stimulates reparative and regenerative processes. The drug has anti-inflammatory, antitumor, antiallergic and detoxifying effects, as well as antioxidant and membrane-stabilizing properties. Derinat normalizes the condition of tissues during dystrophic changes of vascular origin and has a weak anticoagulant effect.

Increases the body's resistance to infections. Stimulates hematopoiesis (normalizing the number of leukocytes, lymphocytes, granulocytes, phagocytes, platelets). Possessing pronounced lymphotropism, Derinat stimulates the drainage and detoxification function of the lymphatic system. Derinat significantly reduces the sensitivity of cells to the damaging effects of chemotherapy drugs and radiation therapy. Stimulation of leukopoiesis during leukopenia caused by polychemotherapy or radiation therapy is observed after a single injection. The use of the drug in the first 24 hours after exposure to radiation accelerates the onset and rate of restoration of stem cells, as well as myeloid, lymphoid and platelet lineages of hematopoiesis.

The drug activates antiviral, antifungal and antimicrobial immunity.

When administered intramuscularly, it increases the activity of phagocytes against Chlamydiaceae, Staphylococcus aureus, Escherichia coli, Helicobacter pylori.

Derinat significantly reduces the sensitivity of cells to the damaging effects of cytotoxic drugs and radiotherapy, which is manifested in a decrease in cardio- and myelotoxicity in cancer patients and the stability of the therapeutic effect with repeated courses of treatment. The drug has a high reparative and regenerative effect.

It has cardioprotective, antihypoxic and angioprotective properties. When Derinat is added to the complex therapy of IHD, the contractile function of the myocardium improves, the death of myocytes is prevented, and tolerance to physical activity increases.

In case of gastric and duodenal ulcers, the drug has a reparative effect, restoration of the mucous membrane and a pronounced immunomodulatory effect aimed at eliminating the infectious factor Helicobacter pylori.

Pharmacokinetics of the drug.

Suction and distribution

Sodium deoxyribonucleate has a high affinity for hematopoietic organs, takes an active part in cellular metabolism, being integrated into cellular structures; quickly absorbed from the injection site with intramuscular administration and distributed through the lymphatic tract in organs and tissues, maximally accumulating in the bone marrow, lymph nodes, thymus, spleen, ovaries, kidneys, to a lesser extent in the liver, brain, stomach, small and colon. During the phase of intensive entry of the drug into the blood, redistribution occurs between plasma and blood cells, in parallel with metabolism and excretion. After a single injection, all pharmacokinetic curves describing changes in the concentration of the drug in the studied organs and tissues are characterized by a rapid phase of increasing and a rapid phase of decreasing concentration in the interval of 5-24 hours. After intramuscular administration, Cmax is reached after 5 hours. The drug penetrates the BBB. Cmax of the drug in the brain is reached after 30 minutes.

Metabolism and excretion

Sodium deoxyribonucleate is metabolized in the body. It is excreted mainly by the kidneys and partly through the intestines. T1/2 with intramuscular administration is 72.3 hours.

Indications for use:

— therapy of radiation injuries;

— myelosuppression and resistance to cytostatics in cancer patients, which developed against the background of cytostatic and/or radiation therapy (stabilization of hematopoiesis, reduction of cardio- and myelotoxicity of chemotherapy drugs);

- stomatitis induced by cytostatic therapy;

- peptic ulcer of the stomach and duodenum; erosive gastroduodenitis;

— obliterating diseases of the vessels of the lower extremities, stage II-III;

- trophic ulcers, long-term non-healing wounds;

- odontogenic sepsis, purulent-septic complications;

— preoperative and postoperative periods (in surgical practice);

- chlamydia, ureaplasmosis, mycoplasmosis;

- endometritis, salpingoophoritis, endometriosis, fibroids;

- prostatitis, benign prostatic hyperplasia;

— chronic obstructive pulmonary diseases;

- pulmonary tuberculosis, inflammatory diseases of the respiratory tract.

Dosage and method of administration of the drug.

Derinat in the form of an injection solution is prescribed to adults intramuscularly in an average single dose of 75 mg (5 ml of a 1.5% solution) with an administration interval.

For ischemic heart disease, 10 injections of the drug are prescribed at an interval of 1 hour.

For gastric and duodenal ulcers, 5 injections are prescribed with an interval of 48 hours.

For oncological diseases - 3-10 injections at an interval of 1 hour.

In gynecology (endometritis, chlamydia, ureaplasmosis, mycoplasmosis, salpingoophoritis, fibroids, endometriosis) - 10 injections with an interval of 1 hour.

In andrology (prostatitis, benign prostatic hyperplasia) - 10 injections with an interval of 1 hour.

For tuberculosis - injections at intervals of hours.

For acute inflammatory diseases - 3-5 injections at an interval of 1 hour.

For chronic inflammatory diseases - 5 injections with an interval of 24 hours, then 5 injections with an interval of 72 hours.

In children, the frequency of intramuscular administration of the drug is the same as in adults. For children under 2 years of age, the drug is prescribed in an average single dose of 7.5 mg (0.5 ml of a 1.5% solution); for children aged 2 to 10 years, a single dose is determined at the rate of 0.5 ml of the drug per year of life. In children over 10 years of age, a single dose is 5 ml of a 1.5% solution, a course dose is up to 5 injections of the drug.

Side effects of Derinat for intramuscular administration:

Possible: in patients with diabetes mellitus, a hypoglycemic effect is observed, which should be taken into account when monitoring blood glucose levels.

Contraindications to the drug:

- hypersensitivity to the components of the drug.

Use during pregnancy and lactation.

A doctor's consultation is required. If it is necessary to prescribe the drug during pregnancy, the expected benefit to the mother and the potential risk to the fetus should be assessed.

Special instructions for the use of Derinat for intramuscular administration.

It is possible to administer the drug subcutaneously.

The drug does not have embryotoxic, teratogenic or carcinogenic effects.

The results of clinical studies allow us to recommend the use of the drug Derinat in the complex therapy of patients with bacterial and viral infections, with chronic recurrent inflammatory diseases of various etiologies that are not amenable to standard therapy; allergic diseases (allergic rhinitis, bronchial asthma, atopic dermatitis, hay fever), incl. including those associated with opportunistic infections; secondary immunodeficiency states of various etiologies, to stimulate reparative and regenerative processes.

The inclusion of Derinat in the traditional treatment regimen for purulent-inflammatory diseases of the ENT organs reduces the time and increases the effectiveness of treatment, and prevents the occurrence of complications.

In the complex therapy of infectious and inflammatory diseases of the urogenital tract, Derinat suppresses the inflammatory response, reduces the frequency and duration of relapses.

The drug potentiates the therapeutic effect of basic therapy for gastric and duodenal ulcers.

Derinat reduces the iatrogenicity of basic drugs in the treatment of rheumatoid arthritis, achieving 50% and 70% improvement in a number of complex indicators of disease activity.

In patients with various surgical pathologies, Derinat significantly accelerates reparative processes in the postoperative period, prevents the development of purulent complications, and reduces the time of hospital treatment. When performing orthopedic and traumatological operations, Derinat accelerates the reparative regeneration of bone tissue.

The clinical effectiveness of administering the drug to patients with severe burns with a high risk of developing infection and already developed complications (pneumonia, sepsis) is manifested in optimizing the course of the wound process, the timing of suppuration and cleansing of the wound and its readiness for surgery.

In case of surgical sepsis, the introduction of Derinat into complex therapy causes a decrease in the level of intoxication, activation of the immune system, normalization of hematopoiesis, and improves the functioning of organs responsible for the processes of detoxification of the internal environment of the body (including lymph nodes, spleen).

Drug overdose:

No negative effects from overdose were identified.

Interaction of Derinat for intramuscular administration with other drugs.

The use of Derinat in complex therapy makes it possible to increase the effectiveness and shorten the duration of therapy, with a significant reduction in doses of antibiotics and antivirals with an increase in periods of remission.

Derinat increases the effectiveness of antitumor antibiotics of the anthracacline series and cytostatics.

Terms of sale in pharmacies.

The drug is available with a prescription.

Terms of storage conditions for the drug Derinat for intramuscular administration.

The drug should be stored in a dry place, protected from light, at a temperature of 4° to 20°C. Shelf life – 5 years.

  • Author: Svetlana
  • Print
  1. 5
  2. 4
  3. 3
  4. 2
  5. 1

note

Dazolic instructions for use, contraindications, side effects, reviews

Antiprotozoal drug. Related PostsDepakin Enteric 300 instructions for use, contraindications, side effects, reviews Diacarb instructions for use.

The material is published for informational purposes only and under no circumstances can it be considered a substitute for medical consultation with a specialist in a medical institution. The site administration is not responsible for the results of using the posted information. For questions of diagnosis and treatment, as well as prescribing medications and determining their dosage regimen, we recommend that you consult a doctor.

Source: http://medistok.ru/d/1546-derinat-dlja-vm-vvedenija-instrukcija-po.html

Derinat - official instructions for use

on medical use of the drug

Registration number:

Trade name of the drug: Derinat ®.

International nonproprietary name:

Dosage form:

Compound:

Active substance: sodium deoxyribonucleate 1.5 g.

Excipients: sodium chloride 0.9 g, water for injection ml

Description: transparent colorless liquid.

Pharmacotherapeutic group:

The drug activates the processes of cellular and humoral immunity. The immunomodulatory effect is due to stimulation of B lymphocytes and activation of T helper cells. Derinat activates the body's nonspecific resistance, optimizing inflammatory reactions and the immune response to bacterial, viral and fungal antigens. Stimulates reparative and regenerative processes. Increases the body's resistance to infections, regulates hematopoiesis (helps normalize the number of leukocytes, lymphocytes, granulocytes, phagocytes, platelets). Possessing pronounced lymphotropism, Derinat stimulates the drainage and detoxification function of the lymphatic system. Derinat significantly reduces the sensitivity of cells to the damaging effects of chemotherapy drugs and radiation therapy. The drug does not have embryotoxic, teratogenic or carcinogenic effects.

Suction and distribution

The drug is quickly absorbed and distributed in organs and tissues via the endolymphatic transport pathway. It has a high affinity for the organs of the hematopoietic system, takes an active part in cellular metabolism, integrating into cellular structures. During the phase of intensive entry of the drug into the blood, redistribution occurs between plasma and blood cells, in parallel with metabolism and excretion. After a single injection, all pharmacokinetic curves describing changes in drug concentration in the studied organs and tissues are characterized by a rapid phase of increase and a rapid phase of decrease in concentration in a time interval of 5-24 hours. The half-life (T1/2) for intramuscular administration is 72.3 hours. Derinat is quickly distributed throughout the body, during daily course use it accumulates in organs and tissues: maximum: - in the bone marrow, lymph nodes, spleen, thymus; to a lesser extent - in the liver, brain, stomach, small and large intestines. The maximum concentration in the bone marrow is determined 5 hours after administration of the drug. The drug crosses the blood-brain barrier. The maximum concentration of the drug in the brain is achieved after 30 minutes.

Metabolism and excretion.

Derinat is metabolized in the body. It is excreted from the body (in the form of metabolites) partially with feces, and, to a greater extent, with urine according to a biexponential dependence.

— myelosuppression and resistance to cytostatics in cancer patients, which developed against the background of cytostatic and/or radiation therapy (stabilization of hematopoiesis, reduction of cardio- and myelotoxicity of chemotherapy drugs);

- stomatitis induced by cytostatic therapy;

- peptic ulcer of the stomach and duodenum, erosive gastroduodenitis;

- cardiac ischemia;

- obliterating diseases of the vessels of the lower extremities, chronic ischemic disease of the lower extremities II - III stages;

- trophic ulcers, long-term non-healing wounds;

- odontogenic sepsis, purulent-septic complications;

— preoperative and postoperative periods (in surgical practice);

- endometritis, salpinoophoritis, endometriosis, fibroids;

- chlamydia, ureaplasmosis, mycoplasmosis;

- prostatitis, benign prostatic hyperplasia;

— chronic obstructive pulmonary diseases;

- pulmonary tuberculosis, inflammatory diseases of the respiratory tract.

Use during pregnancy and lactation

A doctor's consultation is required. If it is necessary to prescribe the drug during pregnancy, the expected benefit to the mother and the potential risk to the fetus should be assessed. During lactation, use strictly as prescribed by a doctor.

Adults: intramuscularly for 1-2 minutes, 5 ml of 1.5% (75 mg) solution, every hour.

For coronary heart disease - 10 injections at an hourly interval.

For gastric and duodenal ulcers - 5 injections with an interval of 48 hours.

For oncological diseases, injections are given at hourly intervals.

In gynecology (endometritis, chlamydia, ureaplasmosis, mycoplasmosis, salpino-oophoritis, fibroids, endometriosis) - 10 injections at an hourly interval.

In andrology (prostatitis, benign prostatic hyperplasia) - 10 injections at an hourly interval.

For pulmonary tuberculosis, injections at hourly intervals.

For acute inflammatory diseases, injections at hourly intervals.

For chronic inflammatory diseases - 5 injections with an interval of 24 hours, then - 5 injections with an interval of 72 hours.

When using a 1.5% solution of 2 ml, intramuscular injections are carried out daily, recalculating, until the course dose is reached.

For children, the drug is prescribed intramuscularly according to the same regimen as for adults. For children under 2 years of age, the drug is prescribed in a single dose of 7.5 mg (0.5 ml). In children aged 2 to 10 years, a single dose is determined at the rate of 0.5 ml of the drug per year of life. From the age of 10, a single dose is 5 ml of a 1.5% solution, a course dose is up to 5 injections (15 mg/ml) of the drug.

In patients with diabetes mellitus, a hypoglycemic effect is observed, which should be taken into account when monitoring blood sugar levels.

No negative effects from overdose were identified.

Interaction with other drugs

The use of Derinat in complex therapy makes it possible to increase the effectiveness and reduce the duration of treatment, with a significant reduction in doses of antibiotics and antiviral agents with an increase in periods of remission.

Derinat increases the effectiveness of antitumor anthracycline antibiotics and cytostatics.

The drug potentiates the therapeutic effect of basic therapy for gastric and duodenal ulcers. Derinat reduces the iatrogenicity of basic drugs in the treatment of rheumatoid arthritis, achieving 50% and 70% improvement in a number of complex indicators of disease activity.

In case of surgical sepsis, the introduction of Derinat into complex therapy causes a decrease in the level of intoxication, activation of the immune system, normalization of hematopoiesis, and improves the functioning of the organs responsible for the processes of detoxification of the internal environment of the body (lymph nodes, spleen, etc.).

The drug can be administered subcutaneously.

Solution for intramuscular administration 15 mg/ml. 5 ml in imported glass vials with injection infusion stoppers in blister trays in a cardboard pack No. 5 or 2 ml in imported glass vials with injection infusion stoppers in blister trays in a cardboard pack No. 10.

5 years. Do not use after the expiration date stated on the packaging.

Store in a place protected from light, out of reach of children, at a temperature of + 4°C to + 20°C.

By doctor's prescription.

CJSC FP Tekhnomedservis, Russia.

Send claims regarding the quality of the drug to:

Source: http://medi.ru/instrukciya/derinat_11411/

DERINAT

◊ Solution for external and local use 0.25% transparent, colorless, without foreign inclusions.

Excipients: sodium chloride, water for injection.

10 ml - dropper bottle (1) - cardboard packs.

10 ml - bottles with a spray nozzle (1) - cardboard packs.

10 ml - glass bottles (1) - cardboard packs.

20 ml - glass bottles (1) - cardboard packs.

An immunomodulator that affects cellular and humoral immunity. Derinat stimulates reparative processes, has an anti-inflammatory effect, normalizes the condition of tissues during dystrophic changes of vascular origin.

The drug activates antiviral, antifungal and antimicrobial immunity, has a high reparative and regenerative effect.

When used externally, Derinat promotes the healing of trophic ulcers, infected wounds and deep burns, significantly accelerating epithelization. Under the influence of Derinat, scarless healing of ulcerative defects on the mucous membrane occurs.

Suction and distribution

Sodium deoxyribonucleate is quickly absorbed when applied topically and distributed through the lymphatic tract to organs and tissues.

Metabolism and excretion

Sodium deoxyribonucleate is metabolized in the body. It is excreted mainly by the kidneys and partly with feces.

As monotherapy:

— prevention and treatment of ARVI;

- inflammatory and dystrophic eye diseases;

- inflammatory diseases of the oral mucosa.

As part of complex therapy:

— chronic inflammatory diseases, fungal, bacterial and other infections of the mucous membranes in gynecology;

— acute and chronic diseases of the upper respiratory tract (rhinitis, sinusitis / including frontal sinusitis, sinusitis/);

- obliterating diseases of the lower extremities;

— infected and long-term non-healing wounds (including diabetes mellitus);

— post-radiation necrosis of the skin and mucous membranes;

Derinat in the form of a solution for external and local use is prescribed depending on the location of the pathological process.

The drug is prescribed to children from the first day of life and to adults.

To prevent ARVI , instill 2 drops into each nasal passage 2-4 times a day for 1-2 weeks. When symptoms of a respiratory disease appear, the drug is instilled 2-3 drops into each nasal passage every 1-1.5 hours during the first day, then 2-3 drops into each nasal passage 3-4 times a day. The duration of the course of therapy is from 5 days to 1 month.

For inflammatory diseases of the nasal cavity and paranasal sinuses, the drug is instilled 3-5 drops into each nasal passage 4-6 times a day; duration of the course days.

For inflammatory diseases of the oral cavity, rinse the mouth with a solution of the drug 4-6 times a day (1 bottle for 2-3 rinses). Duration of therapy: days.

For chronic inflammatory diseases, fungal, bacterial and other infections in gynecological practice - intravaginal administration of tampons with the drug or irrigation of the vagina and cervix 5 ml per procedure 1-2 times a day during the day.

For hemorrhoids, the drug is administered rectally using microenemas. The duration of treatment is 4-10 days.

In ophthalmological practice, for severe inflammatory and dystrophic processes, Derinat is instilled into the eyes, 1-2 drops 2-3 times a day.

For obliterating diseases of the lower extremities, in order to achieve a systemic effect, the drug is instilled 1-2 drops into each nasal passage 6 times a day, the course duration is up to 6 months.

In case of post-radiation necrosis of the skin and mucous membranes, with long-term non-healing wounds, burns, frostbite, trophic ulcers of various etiologies, gangrene, it is recommended to apply application bandages (gauze in 2 layers) to the affected areas with the application of the drug 3-4 times a day or treat the affected area surfaces with the preparation from a spray bottle 4-5 times a day. Course of treatmentmonths.

When applied topically, it is incompatible with fat-based ointments and hydrogen peroxide.

Numerous experimental and clinical laboratory studies have proven the absence of mutagenic, teratogenic, embryotoxic, carcinogenic effects, allergenic properties, and cytogenetic effects; its moderate antimutagenic effect was revealed.

In case of gangrenous processes under the influence of the drug, spontaneous rejection of necrotic masses in the foci of rejection is observed with restoration of the skin. For open wounds and burns, an analgesic effect is noted.

The patient should be warned that before using the drug during pregnancy and lactation, consultation with a doctor is necessary. If it is necessary to prescribe the drug during pregnancy, the expected benefit to the mother and the potential risk to the fetus should be assessed.

The drug should be stored out of the reach of children, in a dry place, protected from light at a temperature of 4° to 20°C. Shelf life – 5 years.

The contents of an opened bottle should be used within two weeks.

To ask a question about the project or contact the editors, use this form.

Source: http://health.mail.ru/drug/derinat/

Derinat ® (Derinat)

Active substance:

Content

Pharmacological group

Nosological classification (ICD-10)

3D images

Compound

Description of the dosage form

Transparent colorless liquid.

pharmachologic effect

Pharmacodynamics

The drug has a modulating effect on the cellular and humoral components of the immune system and nonspecific resistance of the body, which leads to optimization of the inflammatory reaction and specific immune response to bacterial, viral and fungal antigens. The immunomodulatory effect of the drug Derinat ® is due to its ability to stimulate B-lymphocytes, activate T-helper cells and cells of the monocyte-macrophage system. The drug accelerates energy metabolism inside the cell, RNA and DNA synthesis. Activation of cellular immunity by the drug Derinat ® increases the ability of natural killer cells to act on cells affected by viruses, chlamydia, Staphylococcus aureus, Escherichia coli, Helicobacter, etc. Derinat ® stimulates reparative and regenerative processes. The drug has anti-inflammatory, antitumor, antiallergic and detoxifying effects, as well as antioxidant and membrane-stabilizing properties. Derinat ® normalizes the body's condition in case of dystrophies of vascular origin and has a weak anticoagulant effect.

Derinat ® helps remove free radicals from the body and reduces the sensitivity of cells to the damaging effects of chemotherapy drugs.

In the body, the drug accumulates mainly in the organs of the immune system and hematopoiesis - bone marrow, spleen, lymph nodes, as well as in the intestinal epithelium.

Increases the body's resistance to infections. Stimulates hematopoiesis (normalizing the number of leukocytes, lymphocytes, granulocytes, phagocytes, platelets).

Possessing pronounced lymphotropism, Derinat ® stimulates the drainage and detoxification function of the lymphatic system. Derinat ® significantly reduces the sensitivity of cells to the damaging effects of chemotherapy drugs and radiation therapy.

It has cardioprotective, anti-ischemic and cytoprotective effects. When Derinat ® is included in the complex therapy of patients with coronary artery disease, the contractile function of the myocardium improves, the death of cardiomyocytes is prevented, and exercise tolerance increases.

In case of gastric and duodenal ulcers, the drug has a reparative effect, restoration of the mucous membrane and a pronounced immunomodulatory effect aimed at eliminating the infectious factor Helicobacter pylori .

The drug does not have embryotoxic, teratogenic or carcinogenic effects.

Pharmacokinetics

Suction and distribution

The drug is quickly absorbed and distributed in organs and tissues via the endolymphatic transport pathway. It has a high affinity for the organs of the hematopoietic system, takes an active part in cellular metabolism, integrating into cellular structures. During the phase of intensive entry of the drug into the blood, redistribution occurs between plasma and blood cells, in parallel with metabolism and excretion. After a single injection, all pharmacokinetic curves describing changes in the concentration of the drug in the studied organs and tissues are characterized by a rapid phase of increasing and a rapid phase of decreasing concentration in the time interval of 5–24 hours. T1 /2 with intramuscular administration is 72.3 hours. Derinat ® is quickly distributed throughout the body, during daily course use it accumulates in organs and tissues: maximum - in the bone marrow, lymph nodes, spleen, thymus; to a lesser extent - in the liver, brain, stomach, small and large intestines. Cmax is determined 5 hours after drug administration. The drug crosses the BBB. Cmax of the drug in the brain is reached after 30 minutes.

Metabolism and excretion

Derinat ® is metabolized in the body. It is excreted from the body (in the form of metabolites) partially with feces and to a greater extent with urine, according to a biexponential dependence.

Indications of the drug Derinat ®

as part of complex therapy for chronic recurrent inflammatory diseases of various etiologies that are not amenable to standard therapy;

severe influenza, ARVI and their complications (pneumonia, bronchitis, bronchial asthma);

chronic obstructive pulmonary diseases;

as part of complex therapy of bacterial and viral infections;

allergic diseases (allergic rhinitis, bronchial asthma, atopic dermatitis, hay fever);

to activate regenerative processes;

peptic ulcer of the stomach and duodenum, erosive gastroduodenitis;

urogenital infections (chlamydia, ureaplasmosis, mycoplasmosis, including combined virus-associated infections);

endometritis, salpingoophoritis, endometriosis, fibroids;

prostatitis, benign prostatic hyperplasia;

preoperative and postoperative periods (in surgical practice);

cardiac ischemia;

trophic ulcers, long-term non-healing wounds;

obliterating diseases of the vessels of the lower extremities, chronic ischemic disease of the lower extremities of stages II and III;

rheumatoid arthritis, incl. complicated acute respiratory infection or acute respiratory viral infection;

stomatitis induced by cytostatic therapy;

odontogenic sepsis, purulent-septic complications;

myelosuppression and resistance to cytostatics in cancer patients, which developed against the background of cytostatic and/or radiation therapy (stabilization of hematopoiesis, reduction of cardio- and myelotoxicity of chemotherapy drugs);

treatment of radiation injuries;

pulmonary tuberculosis, inflammatory diseases of the respiratory tract;

secondary immunodeficiency states of various etiologies.

Contraindications

Use during pregnancy and breastfeeding

A doctor's consultation is required. If it is necessary to prescribe the drug during pregnancy, the expected benefit to the mother and the potential risk to the fetus should be assessed. During lactation, use strictly as prescribed by a doctor.

Side effects

In patients with diabetes mellitus, a hypoglycemic effect is observed, which should be taken into account when monitoring blood sugar levels.

Interaction

The use of the drug Derinat ® in complex therapy makes it possible to increase the effectiveness and shorten the duration of treatment, with a significant reduction in doses of antibiotics and antivirals with an increase in periods of remission.

Derinat ® increases the effectiveness of antitumor anthracycline antibiotics and cytostatics.

The drug potentiates the therapeutic effect of basic therapy for gastric and duodenal ulcers. Derinat ® reduces the iatrogenicity of basic drugs in the treatment of rheumatoid arthritis, achieving 50 and 70% improvement in a number of complex indicators of disease activity.

In case of surgical sepsis, the introduction of the drug Derinat ® as part of complex therapy causes a decrease in the level of intoxication, activation of the immune system, normalization of hematopoiesis, and improves the functioning of organs responsible for the processes of detoxification of the internal environment of the body (including lymph nodes, spleen).

Directions for use and doses

Adults. 5 ml of a 15 mg/ml solution (75 mg) is administered over 1–2 minutes, with an interval of 24–72 hours.

For acute inflammatory diseases - 3-5 injections with an interval of 24-72 hours.

For chronic inflammatory diseases - 5 injections with an interval of 24 hours, then - 5 injections with an interval of 72 hours.

In gynecology (endometritis, chlamydia, ureaplasmosis, mycoplasmosis, salpingoophoritis, fibroids, endometriosis) - 10 injections with an interval of 24–48 hours.

In urology and andrology (prostatitis, benign prostatic hyperplasia) - 10 injections with an interval of 24–48 hours.

For coronary artery disease - 10 injections with an interval of 48–72 hours.

For gastric and duodenal ulcers - 5 injections with an interval of 48 hours.

For oncological diseases - 3-10 injections with an interval of 24-72 hours.

For pulmonary tuberculosis - 10-15 injections with an interval of 24-48 hours.

For children, the drug is prescribed intramuscularly according to the same regimen as for adults. For children under 2 years of age, the drug is prescribed in a single dose of 7.5 mg (0.5 ml). In children aged 2 to 10 years, a single dose is determined at the rate of 0.5 ml of the drug per year of life. From the age of 10, a single dose is 5 ml of a 15 mg/ml solution, a course dose is up to 5 injections of the drug.

Overdose

No negative effects from overdose were identified.

special instructions

The drug can be administered subcutaneously.

IV administration of the drug is not allowed.

Release form

Solution for intramuscular administration, 15 mg/ml. In bottles made of imported glass with injection infusion stoppers of 2 or 5 ml. In blister trays of 5 (5 ml) or 10 (2 ml) bottles. There is 1 blister tray in a cardboard pack.

Manufacturer

CJSC FP Tekhnomedservis, Moscow, st. Mironovskaya, 33, building 28.

Tel.: ; Fax: .

Conditions for dispensing from pharmacies

Storage conditions for the drug Derinat ®

Keep out of the reach of children.

Shelf life of the drug Derinat ®

Do not use after the expiration date stated on the package.

Synonyms of nosological groups

Prices in Moscow pharmacies

The information is intended solely for comparing prices in stationary pharmacies operating in accordance with Article 55 of the Federal Law “On the Circulation of Medicines” dated April 12, 2010 N 61-FZ.

solution for local and external use 0.25%, 1 pc.

solution for local and external use 0.25%, 1 pc.

solution for local and external use 0.25%, 1 pc.

solution for local and external use 0.25%, 1 pc.

PharmPak LLC (Russia)

solution for intramuscular administration 15 mg/ml, 5 pcs.

solution for intramuscular administration 15 mg/ml, 5 pcs.

PharmPak LLC (Russia)

Reviews

Leave your comment

Current information demand index, ‰

Opinion of “Doctors of the Russian Federation” about the drug Derinat ®

  • First aid kit
  • Online store
  • About company
  • Contacts
  • Publisher contacts:
  • Email:
  • Address: Russia, Moscow, st. 5th Magistralnaya, no. 12.

When quoting information materials published on the pages of the website www.rlsnet.ru, a link to the source of information is required.

©. REGISTER OF MEDICINES OF RUSSIA ® RLS ®

All rights reserved

Commercial use of materials is not permitted

Information intended for healthcare professionals

Source: http://www.rlsnet.ru/tn_index_id_5653.htm